ClinicalTrials.gg
CompletedNCT04994522Updated Apr 6, 2025Results posted

A Study of Belzutifan (MK-6482) in Participants With Renal Impairment (MK-6482-021)

A Phase 1 interventional study of Belzutifan in End Stage Renal Disease and Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies in Kidney Failure, Chronic by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Kidney Failure, Chronic · Merck & Co., Inc.

Enrollment
9th of 12
14 · median 18
Started
2022
with 1 other
Phase 1
10 of 12
none open now
Registered
6th of 12
by date

Among the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc, this one is the 9th largest by enrollment, is one of 2 that started in 2022, is one of 10 in phase 1, and was the 6th registered.

Kidney Failure, Chronic

2,112 studies on the registry are indexed under Kidney Failure, Chronic; 274 are open to participants now.

Browse Kidney Failure, Chronic studies →

Open to participants now

None of the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc is open now. The open studies under Kidney Failure, Chronic, anywhere →

Who these studies take

Of the 169 Kidney Failure, Chronic studies recruiting now, 109 (64%) set no upper age limit and 32 (19%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies in Kidney Failure, Chronic by Merck & Co., Inc as a file.
02

Study summary

The primary purpose of this study is to compare the plasma pharmacokinetics (PK) of belzutifan (MK-6482) following a single oral 120 mg dose in participants with end stage renal disease (ESRD) before and after hemodialysis (HD) to each other and also to that of healthy matched control participants. This study will also evaluate the safety and tolerability of a single oral 120 mg dose of belzutifan in participants with ESRD and the extent of belzutifan removed by HD.

03

Conditions studied

  • End Stage Renal Disease
  • Renal Impairment
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

For Participants With Healthy Renal Function

  • Is in good health based on the opinion of the investigator.
  • Male participants agree to remain abstinent from heterosexual intercourse on a long-term basis or must agree to use as instructed.
  • Female participants must be of nonchildbearing potential.

For Participants With end stage renal disease (ESRD)

  • With exception of the renal impairment, is in good health based on the opinion of the investigator.
  • Has ESRD maintained on stable regimen of at least 3 times per week hemodialysis (HD) for at least 3 months prior to the initial administration of the study intervention.
  • Male participants agree to remain abstinent from heterosexual intercourse on a long-term basis or must agree to use contraception as instructed.
  • Female participants must be of nonchildbearing potential.

Exclusion criteria

Exclusion Criteria:

For Participants With Healthy Renal Function

  • Has a history of endocrine, gastrointestinal (GI), cardiovascular, hematological, hepatic, immunological, renal, respiratory, genitourinary, or major neurological (including stroke and chronic seizures) abnormalities or diseases.
  • Has a history of cancer ().
  • Is positive for surface antigen (HBsAg), antibodies or (HIV).
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
  • Has received any non- starting from 14 days prior to study intervention or is scheduled to receive any non-live vaccine through 30 days following study intervention (except coronavirus disease 2019 [COVID-19]).

Participants With ESRD

  • Has a history of cancer (malignancy).
  • Has required frequent emergent HD (≥3) within a year prior to the initial dose of study intervention.
  • Is positive for HBsAg, hepatitis C antibodies, or HIV.
  • Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit.
  • Has received any non-live vaccine starting from 14 days prior to study intervention or is scheduled to receive any non-live vaccine through 30 days following study intervention (except COVID-19)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Belzutifan in Participants with ESRD

    In period 1, participants with ESRD will receive a single, oral dose of belzutifan 120 mg on Day 1 after HD. In period 2, participants with ESRD will receive a single, oral dose of belzutifan 120 mg on Day 1 before HD. Each period is 4 days.

    Drug: Belzutifan

  • Experimental
    Belzutifan in Healthy Participants

    In period 1, healthy participants will receive a single, oral dose of belzutifan 120 mg on Day 1 of a 4-day period.

    Drug: Belzutifan

Interventions

  • Three 40 mg tablets given as a single oral 120 mg dose.

    Also known as: MK-6482, PT2977, WELIREG

06

What researchers measure

Primary outcomes

  1. Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity (AUC0-inf)

    AUC0-inf was defined as the area under the concentration-time curve of belzutifan from time zero to infinity. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-inf of belzutifan in plasma.

    Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose

  2. Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to 24 (AUC0-24)

    AUC0-24 was defined as the area under the concentration-time curve of belzutifan from time zero to 24 hours postdose. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-24 of belzutifan in plasma.

    Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, and 24 hours postdose

  3. Maximum Plasma Concentration (Cmax) of Belzutifan

    Cmax is the maximum concentration of belzutifan observed in plasma. Blood samples collected predose and at multiple timepoints postdose were used to determine Cmax of belzutifan in plasma.

    Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose

  4. Time to Maximum Plasma Concentration (Tmax) of Belzutifan

    Tmax is the amount of time that belzutifan is present at the maximum concentration observed in plasma. Blood samples collected predose and at multiple timepoints postdose were used to determine Tmax of belzutifan in plasma.

    Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose

  5. Apparent Terminal Half-life (t½) of Plasma Belzutifan

    t1/2 is defined as the time required to divide plasma concentration of belzutifan by half. Blood samples collected predose and at multiple timepoints postdose were used to determine the apparent terminal t1/2 of belzutifan in plasma.

    Time frame: Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose

Secondary outcomes

  1. Dialysis Clearance of Belzutifan Based on Plasma (CLD, Plasma)

    CLD, plasma is defined as a measure of the extent of belzutifan removed by HD. Blood samples collected at pre-dialysis and at multiple timepoints post-dialysis were used to measure the extent of belzutifan in plasma removal by HD.

    Time frame: Pre-dialysis, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours post-dialysis on Day 1 of Period 2 (Study Day ~12)

  2. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who experienced an AE are reported.

    Time frame: Up to 32 days

  3. Percentage of Participants Who Discontinue Study Intervention Due to an AE

    An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who discontinue study intervention due to an AE are reported.

    Time frame: Up to 12 days

07

Results

Posted Apr 6, 2025

Participant flow

Participants with end stage renal diseases (ESRD) and healthy matched control participants were recruited at a single study site in the United States.

Period 1
Participant flow — Period 1
MilestoneBelzutifan in Participants With ESRDBelzutifan in Healthy Participants
Started86
Completed86
Not completed00
Period 2
Participant flow — Period 2
MilestoneBelzutifan in Participants With ESRDBelzutifan in Healthy Participants
Started76
Completed76
Not completed00

Outcome measures

PrimaryArea Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity (AUC0-inf)

AUC0-inf was defined as the area under the concentration-time curve of belzutifan from time zero to infinity. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-inf of belzutifan in plasma.

Time frame:
Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity (AUC0-inf)
ng•hr/mLBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in ESRD After HD (Period 1)Belzutifan in Healthy Participants
Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to Infinity (AUC0-inf)17100 ± 91.321100 ± 91.318500 ± 41.4
PrimaryArea Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to 24 (AUC0-24)

AUC0-24 was defined as the area under the concentration-time curve of belzutifan from time zero to 24 hours postdose. Blood samples collected predose and at multiple timepoints postdose were used to determine AUC0-24 of belzutifan in plasma.

Time frame:
Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, and 24 hours postdose
Reported as:
Geometric mean · ng•hr/mL
Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to 24 (AUC0-24)
ng•hr/mLBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in Participants With ESRD After HD (Period 1)Belzutifan in Healthy Participants
Area Under the Plasma Concentration Time Curve of Belzutifan From Hour 0 to 24 (AUC0-24)10700 ± 50.512300 ± 50.713200 ± 30.7
PrimaryMaximum Plasma Concentration (Cmax) of Belzutifan

Cmax is the maximum concentration of belzutifan observed in plasma. Blood samples collected predose and at multiple timepoints postdose were used to determine Cmax of belzutifan in plasma.

Time frame:
Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of Belzutifan
ng/mLBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in Participants With ESRD After HD (Period 1)Belzutifan in Healthy Participants
Maximum Plasma Concentration (Cmax) of Belzutifan1110 ± 44.0907 ± 46.71300 ± 26.1
PrimaryTime to Maximum Plasma Concentration (Tmax) of Belzutifan

Tmax is the amount of time that belzutifan is present at the maximum concentration observed in plasma. Blood samples collected predose and at multiple timepoints postdose were used to determine Tmax of belzutifan in plasma.

Time frame:
Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose
Reported as:
Median · hour
Time to Maximum Plasma Concentration (Tmax) of Belzutifan
hourBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in Participants With ESRD After HD (Period 1)Belzutifan in Healthy Participants
Time to Maximum Plasma Concentration (Tmax) of Belzutifan2.00 (1.00 to 3.00)4.00 (1.50 to 9.00)1.00 (0.50 to 3.00)
PrimaryApparent Terminal Half-life (t½) of Plasma Belzutifan

t1/2 is defined as the time required to divide plasma concentration of belzutifan by half. Blood samples collected predose and at multiple timepoints postdose were used to determine the apparent terminal t1/2 of belzutifan in plasma.

Time frame:
Predose, and at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, and 72 hours postdose
Reported as:
Geometric mean · hour
Apparent Terminal Half-life (t½) of Plasma Belzutifan
hourBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in Participants With ESRD After HD (Period 1)Belzutifan in Healthy Participants
Apparent Terminal Half-life (t½) of Plasma Belzutifan15.1 ± 68.117.1 ± 57.613.9 ± 20.9
SecondaryDialysis Clearance of Belzutifan Based on Plasma (CLD, Plasma)

CLD, plasma is defined as a measure of the extent of belzutifan removed by HD. Blood samples collected at pre-dialysis and at multiple timepoints post-dialysis were used to measure the extent of belzutifan in plasma removal by HD.

Time frame:
Pre-dialysis, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, and 4 hours post-dialysis on Day 1 of Period 2 (Study Day ~12)
Reported as:
Geometric mean · mL/min
Dialysis Clearance of Belzutifan Based on Plasma (CLD, Plasma)
mL/minBelzutifan in Participants With ESRD Before HD (Period 2)
Dialysis Clearance of Belzutifan Based on Plasma (CLD, Plasma)78.4 ± 53.5
SecondaryPercentage of Participants Who Experienced an Adverse Event (AE)

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who experienced an AE are reported.

Time frame:
Up to 32 days
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of ParticipantsBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in Participants With ESRD After HD (Period 1)Belzutifan in Healthy Participants
Percentage of Participants Who Experienced an Adverse Event (AE)14.30.016.7
SecondaryPercentage of Participants Who Discontinue Study Intervention Due to an AE

An AE is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE. The percentage of participants who discontinue study intervention due to an AE are reported.

Time frame:
Up to 12 days
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Discontinue Study Intervention Due to an AE
Percentage of ParticipantsBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in Participants With ESRD After HD (Period 1)Belzutifan in Healthy Participants
Percentage of Participants Who Discontinue Study Intervention Due to an AE0.00.00.0

Adverse events

Collected over Up to 32 days.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Belzutifan in Participants With ESRD Before HD (Period 2)0/7 (0%)1/7 (14.3%)0/7 (0%)
Belzutifan in Participants With ESRD After HD (Period 2)0/8 (0%)0/8 (0%)0/8 (0%)
Belzutifan in Healthy Participants0/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent serious events
Most frequent serious events
EventBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in Participants With ESRD After HD (Period 2)Belzutifan in Healthy Participants
BacteraemiaInfections and infestations1/70/80/6
Most frequent other events
Most frequent other events
EventBelzutifan in Participants With ESRD Before HD (Period 2)Belzutifan in Participants With ESRD After HD (Period 2)Belzutifan in Healthy Participants
HeadacheNervous system disorders0/70/81/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Belzutifan in Participants With ESRDBelzutifan in Healthy ParticipantsTotal
Mean57.3 ± 8.4855.5 ± 7.4256.5 ± 7.79
Sex: Female, Male
Sex: Female, Male(Participants)Belzutifan in Participants With ESRDBelzutifan in Healthy ParticipantsTotal
Female8614
Male000
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Belzutifan in Participants With ESRDBelzutifan in Healthy ParticipantsTotal
Hispanic or Latino213
Not Hispanic or Latino6511
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Belzutifan in Participants With ESRDBelzutifan in Healthy ParticipantsTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American729
White044
More than one race101
Unknown or Not Reported000
08

Study locations

1 site
  • Orlando Clinical Research Center ( Site 0001)
    Orlando, Florida 32809, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2022 to primary completion in Apr 2024, 20 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 46 industry-sponsored phase 1 interventional studies under Kidney Failure, Chronic, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 20 months is above that.

Counting every sponsor, half of 67 studies reached it within 12 months; a quarter within 5 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 2, 2021
First posted
Aug 6, 2021
StartActual
Jul 12, 2022
Primary completionActual
Apr 1, 2024
CompletionActual
Apr 11, 2024
Results first posted
Apr 6, 2025
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04994522
Responsible party
Sponsor
First posted
Aug 6, 2021
Start date
Jul 12, 2022
Primary completion
Apr 1, 2024
Completion
Apr 11, 2024
Results posted
Apr 6, 2025
Last update
Apr 6, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Belzutifan

Start the discussion